D
12.66
-0.01 (-0.08%)
| Previous Close | 12.67 |
| Open | 12.75 |
| Volume | 327,831 |
| Avg. Volume (3M) | 393,891 |
| Market Cap | 418,019,264 |
| Price / Earnings (Forward) | 93.46 |
| Price / Sales | 8.12 |
| Price / Book | 5.90 |
| 52 Weeks Range | |
| Earnings Date | 24 Mar 2025 - 28 Mar 2025 |
| Profit Margin | -26.38% |
| Operating Margin (TTM) | 3.24% |
| Diluted EPS (TTM) | -0.450 |
| Quarterly Revenue Growth (YOY) | 530.30% |
| Total Debt/Equity (MRQ) | 1.27% |
| Current Ratio (MRQ) | 15.95 |
| Operating Cash Flow (TTM) | -6.89 M |
| Levered Free Cash Flow (TTM) | -7.11 M |
| Return on Assets (TTM) | -1.51% |
| Return on Equity (TTM) | -28.13% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Bearish |
| Medical Devices (Global) | Bearish | Bearish | |
| Stock | Delcath Systems, Inc. | Bullish | Bullish |
AIStockmoo Score
0.9
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.88 |
|
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 2.73% |
| % Held by Institutions | 45.01% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 29.00 (HC Wainwright & Co., 129.07%) | Buy |
| Median | 27.00 (113.27%) | |
| Low | 25.00 (Stephens & Co., 97.47%) | Buy |
| Average | 27.00 (113.27%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 14.69 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stephens & Co. | 23 Jun 2025 | 25.00 (97.47%) | Buy | 13.26 |
| HC Wainwright & Co. | 23 May 2025 | 29.00 (129.07%) | Buy | 16.11 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 22 May 2025 | Announcement | Delcath Systems Issues Full Year 2025 Guidance |
| 15 May 2025 | Announcement | Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference |
| 09 May 2025 | Announcement | Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 08 May 2025 | Announcement | Delcath Systems Reports First Quarter 2025 Results and Business Highlights |
| 28 Apr 2025 | Announcement | Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer |
| 24 Apr 2025 | Announcement | Delcath Systems to Host First Quarter 2025 Earnings Call |
| 09 Apr 2025 | Announcement | Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |